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ABSTRACT 
Objectives: Primary aldosteronism (PA) is characterized by the autonomous overproduction of al-
dosterone. Its prevalence has increased since the use of the aldosterone (ALD)/plasma renin activity 
(PRA) ratio (ARR). The objective of this study is to determine ARR and ARC (ALD/plasma renin con-
centration ratio) cut-off values (COV) and their diagnostic concordance (DC%) in the screening for 
PA in an Argentinian population. Design: multicenter prospective study. Subjects and methods: We 
studied 353 subjects (104 controls and 249 hypertensive patients). Serum aldosterone, PRA and ARR 
were determined. In 220 randomly selected subjects, 160 hypertensive patients and 60 controls, 
plasma renin concentration (PRC) was simultaneously measured and ARC was determined. Results: 
According to the 95th percentile of controls, we determined a COV of 36 for ARR and 2.39 for ARC, 
with ALD ≥ 15 ng/dL. In 31/249 hypertensive patients, ARR was ≥ 36. PA diagnosis was established 
in 8/31 patients (23/31 patients did not complete confirmatory tests). DC% between ARR and ARC 
was calculated. A significant correlation between ARR and ARC (r = 0.742; p < 0.0001) was found 
only with PRA > 0.3 ng/mL/h and PRC > 5 pg/mL. DC% for ARR and ARC above or below 36 and 2.39 
was 79.1%, respectively. Conclusion: This first Argentinian multicenter study determined a COV of 
36 for ARR and 2.39 for ARC. Applying an ARR ≥ 36 in the hypertensive group, we confirmed PA in a 
higher percentage of patients than the previously reported one in our population. As for ARC, further 
studies are needed for its clinical application, since DC% is acceptable only for medium range renin 
values. Arch Endocrinol Metab. 2015;59(5):441-7
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INTRODUCTION 
P rimary aldosteronism (PA) described by Jerome Conn in 1955 (1) is a relatively common curable 
cause of hypertension (HT). Since Hiramatsu and cols. 
reported that the aldosterone (ALD)/plasma renin ac-
tivity (PRA) ratio (ARR) showed a higher sensitivity 
for detecting PA (2), various research groups applied 
ARR to detect PA in essential hypertensive patients, 
independently of the potassium levels. Thus, PA preva-
lence increased to a mean of 7.8% -higher than the 1% 
historically reported one in hypokalemic hypertensive 
patients (3). Furthermore, recent studies have reported 
the ALD/plasma renin concentration (PRC) ratio as 
an alternative method of screening (4,5).
We performed a prospective multicenter study in 
order to determine firstly the cut-off value (COV) for 
ARR in our population as a screening test for PA in 
hypertensive patients, regardless of the potassium le-
vel (6). Additionally, in a randomly selected subgroup, 
PRC was simultaneously measured. The aim of this pa-
per is to present our results, to determine the ALD/
PRC ratio (ARC) and to compare ARR and ARC in 
order to assess the possible clinical application of ARC 
by calculating the diagnostic concordance (DC%) be-
tween both ratios.
SUBJECTS AND METHODS 
We performed a prospective multicenter study at the 
Adrenal Department of the Argentine Society of Endo-
crinology and Metabolism, comprising 10 hospitals of 
Buenos Aires. Four hundred and forty subjects of both 
sexes were recruited in a three-year period. Eighty-sev-
en subjects were excluded due to heart, liver or kid-
ney failure, chronic neuropathy, Cushing’s syndrome, 
glucocorticoid therapy, hyperthyroidism, untreated 
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hypothyroidism, hypercalcemia, diabetes mellitus, sec-
ondary HT, hormone replacement therapy or missing 
data. The remaining 353 subjects were divided into 
two groups: 1) Controls: 104 subjects (68 females and 
36 males), aged 16 to 77 years old, with blood pressure 
(BP) measurements ≤ 139/85 mmHg and no first-
degree family history of HT. 2) Hypertensive group: 
249 patients (193 females and 56 males), aged 17 to 
76 years old, with BP measurements ≥ 140/90 mmHg. 
In both groups, the following data was obtained: 
waist circumference, weight, height, body mass index 
(BMI) and sitting BP, which was measured on three 
different days. Serum levels of sodium, potassium, cal-
cium, urea, creatinine, cholesterol, LDL-C, HDL-C, 
triglycerides, ALD and PRA were determined. Waist 
circumference less than 102 cm in males and 88 cm in 
females was considered normal. Hypokalemia was de-
fined as serum potassium concentration < 3.5 mEq/l. 
PRC was simultaneously measured in a subgroup 
of 220 randomly selected subjects, 60 controls (52 fe-
males and 8 males) and 160 hypertensive patients (111 
females and 49 males). 
Approval was obtained from each hospital ethical 
committee. Informed consent was obtained from all 
subjects. 
Preanalytical conditions
Preanalytical conditions were unified and samples were 
processed in a single laboratory.
Prior to performing baseline sample collection, un-
restricted sodium diet was indicated for seven days and 
potassium was added if needed. Treatments that stron-
gly interfere with the renin-angiotensin system were 
not allowed; the washout period was 15 days for beta
-adrenergic blockers, angiotensin II receptor blockers 
(ARBs) and diuretics and 6 weeks for spironolactone. 
a-adrenergic blockers, angiotensin converting enzy-
me inhibitors (ACE-I) and calcium channel blockers 
(CCBs) were allowed. 
Fasting blood samples were drawn from subjec-
ts seated for 15 minutes and after at least 2 hours of 
upright posture between 8.00 and 9.00 AM. Serum 
samples were used for ALD and PRC and clinical che-
mistry determination while Na2-EDTA treated plasma 
samples, obtained by centrifugation at 4°C and inten-
ded for PRA measurement, were immediately frozen 
at -20°C until assayed. Each aliquot was thawed once. 
In all cases, lipemic and/or hemolyzed samples were 
excluded.
Assay methods and measurements
ALD was measured by a solid-phase RIA (DPC), with 
a functional sensitivity of 2 ng/dL (20 pg/mL) and in-
tra- and interassay precision of 5.4% and 15.7%, respec-
tively. Reference range for an ambulatory individual on 
a normal sodium diet and in an upright position: 4-30 
ng/dL (40-300 pg/mL).
PRA was measured by a solid-phase RIA (DIA SO-
RIN) that measures angiotensin I (AT I) generated in 
vitro, as described by Sealey (7), with an analytical sen-
sitivity of 0.018 ng AT/tube, and an intra- and interas-
say precision of 10%. 
PRC was measured by a solid-phase IRMA DSL 
(Diagnostic Systems Laboratories) with an analytical 
and functional sensitivity of 0.36 and 5.0 pg/mL, res-
pectively, and an intra- and interassay precision of 10%. 
This method has been standardized against the second 
reference standard IRP 68/356.
The upper limit of the reference range in ambula-
tory subjects on a normal sodium diet and in an upright 
position is 3.3 ng/mL/h for ARP and 65 pg/mL for 
PRC. 
The ARR [ALD (ng/dL)/PRA (ng/mL/hour)] 
and the ARC [ALD (ng/dL)/PRC (pg/mL)] were 
calculated in hypertensive patients, ARR values were 
considered suspicious for PA only with ALD ≥ 15 ng/dL, 
in agreement with other authors (8,9). 
 Fludrocortisone suppression tests (FST) or saline 
infusion tests (SIT) were used to confirm PA, accor-
ding to each participating center. In the FST, ALD was 
measured at baseline and at 10.00 AM on the fifth day 
after administration of fludrocortisone (0.1 mg every 6 
hours for four days on an unrestricted sodium diet) and 
in the SIT, ALD was measured after a 4-hour infusion 
of two liters of saline solution (0.9%). PA was confir-
med with ALD levels above 6 ng/dL in the FST (10) 
and above 7 ng/dL in the SIT (11). In all PA patien-
ts, adrenal computed tomography was obtained, and 
in two of them (1 adenoma and 1 hyperplasia) adrenal 
venous catheterization was performed (9).
Diagnostic concordance assessment (DC%)
Since PRC measures renin mass concentration and 
PRA estimates renin enzymatic activity and their results 
are expressed in different units, both values cannot be 
directly compared. Therefore, we calculated the DC% 
in order to determine if the results obtained by both 
methods (ARR and ARC) are comparable or provide, 
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at least, the same diagnostic information. DC% is the 
percentage obtained from adding the concordant re-
sults below (A) and above (B) the COV for ARR and 
ARC, respectively, divided by the total number of re-
sults (concordant and discordant) multiplied by 100: 
DC% = {(A+B) / total Nº of results} x100. 
Statistical analyses
Normality of variables was analyzed with the Shapiro- 
Wilks test. Comparisons were made by the non-para-
metric Wilcoxon test. Differences between control 
subjects, essential hypertensive patients and PA hyper-
tensive patients were compared by a non-parametric 
variance analysis using the Kruskal Wallis test; for post-
hoc comparisons, the Conover method was used. The 
relationship between variables was analyzed using the 
non-parametric Spearman coefficient of correlation (r) 
and its corresponding test to determine whether the 
correlation is significantly different from zero. Signifi-
cance was set at p < 0.05. 
In order to calculate the cut-off values for ARR and 
ARC, the Collings and Hamilton method and/or the 
determination of the 95th percentile were used. 
RESULTS  
Control subjects had a mean age lower than hyperten-
sive patients (45.2 ± 13.8 vs. 51 ± 13.6); however, the 
median (47 vs. 53 years) and the range (16-77 vs. 17-76 
years) were similar. Both BMI and waist circumference 
were significantly higher in hypertensive subjects than 
in controls (p < 0.0001). Hypertensive subjects had a 
significantly higher serum concentration of creatinine 
(p = 0.0001), total cholesterol (p = 0.0165), LDL-
C (p = 0.0344) and triglycerides (p < 0.0001), while 
the HDL-C concentration was significantly lower (p = 
0.0078). They also had a higher prevalence of meta-
bolic syndrome according to the National Cholesterol 
Education Program–Adult Treatment Panel III (ATP 
III) (12). No significant differences were found in 
blood sodium, glucose or potassium levels (Table 1).
ALD concentrations were similar in both groups, 
while PRA was significantly lower in hypertensive pa-
tients (p = 0.0036). Consequently, higher values of 
ARR were found in hypertensive patients, a finding that 
reached statistical significance (p = 0.0002). 
Since the ARR variable did not show a normal dis-
tribution, the cut-off value according to the 95th per-
centile was 36.15. If the 95th percentile is calculated 
by estimating the empirical distribution function using 
Collings and Hamilton’s method, the COV was 35.79. 
According to both results, the COV for ARR was set at 
36 (Figure 1).
Table 1. Clinical and biochemical characteristics of control subjects and 
hypertensive patients
Variable Controlsn = 104
Hypertensives
n = 249 p
Age (years) 45.18 ± 13.78 51.0 ± 13.6 0.0001
Weight (kg) 65.68 ± 16.13 78.0 ± 17.3 < 0.0001
Height (m) 1.61 ± 0.08 1.61 ± 0.09 NS
BMI (weight/height2) 25.25 ± 5.19 29.9 ± 6.0 < 0.0001
Waist (cm) 83.63 ± 15.32 95.2 ± 15.7 < 0.0001
SBP (mmHg) 114.53 ± 11.16 152.5 ± 19.1 < 0.0001
DBP (mmHg) 73.05 ± 8.03 93.8 ± 11.7 < 0.0001
Creatinine (mg%) 0.82 ± 0.13 0.91 ± 0.19 0.0001
Potassium (mEq/l) 4.26 ± 0.37 4.21 ± 0.49 NS
Sodium (mEq/l) 139.97 ± 3.23 140.8 ± 2.9 NS
Cholesterol (mg%) 202.44 ± 33.86 214.2 ± 39.6 0.0165
HDL cholesterol (mg%) 55.11 ± 12.94 51.2 ± 12.15 0.0078
Triglycerides (mg/dL) 106.33 ± 41.57 143.8 ± 73.2 < 0.0001
LDL cholesterol (mg%) 126.79 ± 30.82 135.9 ± 36.6 0.0344
Blood calcium (mg%) 9.34 ± 0.43 9.33 ± 0.61 NS
Blood glucose (mg%) 92.81 ± 11.56 96.7 ± 8.1 NS
ALD (ng/dL) 16.23 ± 8.78 19.03 ± 14.91 NS
PRA (ng/mL/h) 1.84 ± 1.27 1.54 ± 1.38 0.0036
ARR 12.96 ± 10.23 29.9 ± 59.7 0.0002
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; ALD: 
aldosterone; ARP: plasma renin activity; ARR: aldosterone/plasma renin activity ratio; NS: not 
significant. To convert aldosterone from ng/dL to pmol/l, multiply by 27.7. Values are expressed 
as mean ± standard deviation.
Figure 1. Histogram of aldosterone/plasma renin activity ratio (ARR) 
values in the 104 controls. The line represents the 95th percentile 
corresponding to a value of 36.
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In 12.45% of hypertensive patients (31/249), the 
ARR was ≥ 36 with ALD levels ≥ 15 ng/dL. In 8 sub-
jects (4 males and 4 females) confirmation tests were 
performed, and PA was diagnosed in all cases. The ran-
ge of post-suppression ALD levels was 12-25 ng/dL. 
Seven patients had aldosterone-producing adenomas 
(APA) and the remaining one had idiopathic hyperpla-
sia. Compared to all other hypertensive subjects, PA pa-
tients showed higher ALD and ARR values (p = 0.001) 
and significantly lower potassium concentrations (p = 
0.001). In the PA patients, 7/8 had kalemia < 3.5 mE-
q/l and 1/8, 3.7 mEq/l (Table 2). 
correlation between PRC and PRA only in the 143 patients 
with PRC values between 5 and 20 pg/mL (p < 0.001).  
Table 2. Serum concentration of ALD, PRA, ARR and blood potassium in 
hypertensive patients with primary aldosteronism (PA) and without PA 
(non-PA) 
Variable non- PA  n = 241
PA
n=8 p
ALD ng/dL 17.6 ± 10.07 61.2 ± 47.9 0.001
PRA ng/mL/h 1.58 ± 1.38 0.34 ± 0.33 0.001
ARR 22.3 ± 26.44 258 ± 202 0.001
Blood potassium (mEq/l) 4.25 ± 0.41 2.94 ± 0.72 0.001
ALD: serum aldosterone; PRA: plasma renin activity; ARR: aldosterone/plasma renin activity 
ratio. To convert aldosterone from ng/dL to pmol/l, multiply by 27.7. Results are expressed as 
mean ± standard deviation.
PA was confirmed in 3.2% of our hypertensive pa-
tients but, since the confirmatory diagnostic evaluation 
could not be completed in the remaining 23 patients 
with ARR ≥ 36, the actual prevalence rate cannot be 
accurately established. 
No correlation was found between the severity of 
HT and ARR either in the hypertensive group as a 
whole or in the PA patients. Likewise, no correlation 
was found between ARR levels and systolic and dias-
tolic blood pressure (SBP and DBP, respectively) using 
the Spearman coefficient of correlation.
In the hypertensive group – with or without PA – no 
significant differences were found in BMI, waist circum-
ference, SBP and DBP readings, plasma concentrations of 
HDL-C, LDL-C, triglycerides, cholesterol and glucose.
PRC subgroup 
In this subgroup, neither PRA nor PRC showed signifi-
cant differences between controls and HT. ALD levels 
were significantly higher in hypertensive patients than 
in controls (Table 3). 
The analysis of the relationship between PRC and 
PRA, both in the whole group and in the subgroup of 
hypertensive patients (Spearman r), showed a significant 
Table 3. Plasma concentration of ALD, PRA, PRC, ARR and ARC in control 
subjects and in hypertensive patients 
Variable Controlsn = 60
Hypertensives
n = 160 p
ALD (ng/dL) 14.36 ± 8.70 19.69 ± 17.27   0.007
PRA (ng/mL/h) 1.53 ± 1.12 1.50 ± 1.33 NS
PRC (pg/mL) 13.92 ± 11.13 13.25 ± 13.64 NS
ARR 14.43 ± 12.50 29.45 ± 57.39 0.018
ARC 1.39 ± 1.31 2.28 ± 3.10 0.001
ALD: aldosterone; PRA: plasma renin activity; PRC: plasma renin concentration; ARR: 
aldosterone/plasma renin activity ratio; ARC: aldosterone/plasma renin ratio; NS: not significant. 
To convert aldosterone from ng/dL to pmol/l, multiply by 27.7. Values are expressed as mean 
± standard deviation.
As the ARC variable did not show a normal distri-
bution, the cut-off value according to the 95th percenti-
le was 2.41 when it was directly calculated. If it is calcu-
lated by estimating the empirical distribution function 
using the method proposed above, the COV is 2.39.  
In the 220 subjects evaluated, we found a significant 
correlation between ARR and ARC (r = 0.742; p < 0.0001) 
results, which was similar in the control group and in the 
hypertensive patients – which included 5/8 PA patients.  
Even though ARR and ARC are not comparable 
in absolute values, the percentage of consistent resul-
ts above or below 36 for ARR and 2.39 for ARC was 
79.1%: [(153+21)/220]x100. Therefore, the DC% be-
tween the results of ratios is 79.1% (Figure 2). 
Figure 2. Diagnostic concordance between aldosterone/renin ratio (ARC) 
and aldosterone/plasma renin activity ratio (ARR). Results in primary 
aldosteronism (PA) hypertensive patients and non-PA hypertensive 
patients are shown. Areas A and B represent concordant results; areas C 
and D represent non-concordant results. (A) Results below the cut-off 
values (COV) by both methods. (B) Results above the COV by both 
methods. (C) Results below the COV for ARR and above the COV for ARC. 
(D) Results above the COV for ARR and below the COV for ARC.
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If results are evaluated according to PRA and PRC 
ranges studied, discordance between ARR and ARC is 
greater in samples with PRA below 0.3 ng/mL/h and 
PRC below 5.0 pg/mL than in samples with medium 
to high levels (Table 4).  
PA prevalence ranges from 0.7 to 27% with a mean 
of 7.8% (3). In agreement with our data, a multicenter 
study in 1236 unselected hypertensive patients found a 
prevalence of PA of 3.3% (19). 
Although PA prevalence has been reported to in-
crease according to HT severity (20,21), we have not 
observed a correlation between ARR and higher blood 
pressure in hypertensive subjects as a whole or in PA pa-
tients, in accordance with Bussolengo’s findings (22). 
In our hypertensive patients, we ensured an ade-
quate sodium and potassium supply before sampling 
and appropriate washout periods from diuretics, beta
-adrenergic blockers, ARBs and spironolactone. Treat-
ment with ACE-I, a-adrenergic blockers and CCBs was 
allowed, as these drugs have little or no impact on the 
renin-angiotensin system (23). There is no agreement 
on this point among different authors. According to 
clinical practice guidelines, only drugs with minimal or 
no effects on plasma ALD levels, such as non-dihydro-
pyridine CCBs, hydralazine and a-adrenergic blockers 
(prazosin, doxazosin, terazosin), can be used for the 
control of blood pressure during screening tests (24). 
Nevertheless, according to Young, the study is valid 
even under treatment with ACE-I and ARBs, since low 
renin levels in these conditions would increase the de-
gree of suspicion of PA (9).
In our study, we observed an increased prevalen-
ce of metabolic syndrome in hypertensive patients as 
compared with controls, but in agreement with other 
reports (25), we found no differences between PA and 
essential hypertensive patients. Neither Fallo and cols. 
(26) nor Catena and cols. (27) found differences in the 
lipid profile between PA patients and those with essen-
tial hypertension, despite the higher prevalence of me-
tabolic syndrome and insulin resistance in PA patients 
versus controls. Furthermore, ALD may exert a direct 
effect on insulin receptor function (28) and decrease 
insulin sensitivity in human adipocytes (29). 
There was no correlation between age and ALD 
concentration or PRA either in controls or in hyperten-
sive patients (data not shown). This is consistent with 
findings reported by other authors evaluating normo-
tensive subjects (30) and hypertensive patients (31), 
but it differs from other author’s reports (32), where 
both ALD and PRA were found to decrease with age.  
In our study, eight PA cases were confirmed in 
249 hypertensive patients. Unlike other studies, the 7 
patients with APA had hypokalemia. This situation is 
usually associated with disturbances of internal milieu, 
Table 4. DC% observed between ARR and ARC results in samples 
selected according to the levels of PRC or PRA 
Selection criterion: ARR and ARC results 
obtained from samples with: DC%
PRC < 5 pg/mL 68
PRC > 5 pg/mL 88
PRA < 0.3 ng/mL/h 59
PRA 0.3-3.3 ng/mL/h 86
PRA > 3.3 ng/mL/h 87
DC%: diagnostic concordance; ARR: aldosterone/plasma renin activity ratio; ARC: aldosterone/
plasma renin ratio; PRC: plasma renin concentration; PRA: plasma renin activity. 
DISCUSSION
In our control group, the cut-off value for ARR was 
set at 36. ARR may be significantly modified by a de-
crease in PRA levels, which does not necessarily imply 
the presence of autonomous ALD secretion; therefore 
many authors only take into account the ARR value 
when serum ALD levels exceed a specific concentra-
tion (8,9,13). Thus, we required an ALD concentration 
≥ 15 ng/dL as a further requisite for applying ARR 
in our hypertensive patients. According to these crite-
ria, the estimated PA prevalence would be 3.2%, but 
this percentage is most probably not representative of 
the true PA prevalence, since confirmatory tests could 
be performed only in 8/31 patients with ARR ≥ 36. 
Unfortunately, 23/31 patients with ARR ≥ 36 did not 
return to perform these tests – despite being repeatedly 
called for this purpose. Nevertheless, the percentage we 
found in our study is still higher than the previously 
reported one (0.82%) in a population of Buenos Aires, 
where the screening for PA was based on the criteria of 
hypertension and hypokalemia (14). 
ARR is widely used as a screening test for PA in 
hypertensive patients. However, its results may be mo-
dified by factors such as patient selection, sampling con-
ditions, sample storage and processing, absence of stan-
dardized laboratory methods and variations in PRA and 
ALD due to geographical location and ethnicity (13-
18) – leading to difficulties in establishing a universal 
cut-off value. Thus, published reports show a wide ran-
ge of ARR cut-off levels – between 20 and 100, althou-
gh most authors report values between 25 and 40 (3). 
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as reported in the PAPY study, where a higher prevalen-
ce of hypokalemia was shown in subjects with adenoma 
(48%) than in those with hyperplasia (17%) (21).
Regarding PRC determination, this methodology 
has many advantages over PRA (33,34): less demanding 
preanalytical conditions (serum vs. plasma), shorter in-
cubation times and direct measurement of the renin 
molecule, which makes it more applicable to the clini-
cal diagnostic laboratory and less operator-dependent, 
narrowing interlaboratory coefficients of variation. This 
method is calibrated against the WHO standard IRP 
68/356 (NIBSC), which ensures traceability. Additio-
nally, in recent years automated methodology for PRC 
measurement has been developed. The disadvantages in-
clude greater prorenin cryoactivation effects and less sen-
sitivity when measuring low renin concentrations (35). 
Since PRC and ALD/renin ratio have been proposed for 
PA screening (4,5), we determined PRC in a subgroup 
of randomly selected controls and hypertensive patients. 
PRC and PRA results have a significant correlation 
in subjects with PRC values ranging between 5 and 20 
pg/mL (p < 0.001). A significant correlation was also 
found between ARR and ARC both in controls and 
hypertensive patients (p < 0.0001).
PRA and PRC are not comparable in absolute values 
because PRC measures renin concentration, while PRA 
measures enzyme activity and their results are expressed 
in different units. When comparing ARR vs. ARC, the 
diagnostic concordance of values above or below 36 or 
2.39 for ARR and ARC respectively, was 79.1%. Our 
comparative analysis of ARR and ARC data shows that 
DC% is acceptable only for PRA values ≥ 0.3 ng/mL/h 
(86%) and PRC ≥ 5.0 pg/mL (88%). 
In conclusion, this first multicenter prospective stu-
dy performed in Argentina establishes a cut-off value 
for ARR in our population. In hypertensive patients, 
we consider ARR ≥ 36 along with ALD ≥ 15 ng/dL, 
as suspicious for PA. Applying an ARR ≥ 36 in the 
hypertensive group, and even taking into consideration 
that confirmatory tests could not be performed in all 
hypertensives with ARR ≥ 36, we found that PA was 
confirmed in a higher percentage of patients than the 
previously reported one in our population. As for ARC, 
further studies are needed for its clinical application, 
since the diagnostic concordance between ARR and 
ARC is acceptable only for medium range renin values.
Fundings: this research did not receive any specific grant from any 
funding agency in the public, commercial or not-for-profit sector. 
Disclosure: no potential conflict of interest relevant to this article 
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